Shanghai Shyndec Pharmaceutical (SHA:600420) obtained drug registration from China's medical products regulator for sodium hyaluronate eye drops.
The drug is used to treat corneal and conjunctival epithelial injury, according to a Friday filing with the Shanghai bourse.
Shares of the company closed 4% lower Friday.